Table 2.
In-hospital transplantation-related parameters.
| Variables | Total (n = 301) | ENPH (n = 69) | ENAH (n = 164) | NN (n = 68) | P value |
|---|---|---|---|---|---|
| Diagnosis | |||||
| Acute lymphoblastic leukemia | 107 (35.5) | 16 (23.2) | 70 (42.7) | 21 (30.9) | 0.012 |
| Acute myeloid leukemia | 130 (43.2) | 36 (52.2) | 62 (37.8) | 32 (47.1) | 0.099 |
| Othera | 64 (21.3) | 17 (24.6) | 32 (19.5) | 15 (22.1) | 0.672 |
| Transplant type | 0.033 | ||||
| Autologous HSCT | 42 (14.0) | 7 (10.1) | 19 (11.6) | 16 (23.5) | |
| Allogeneic HSCT | 259 (86.0) | 62 (89.9) | 145 (88.4) | 52 (76.5) | |
| Donor type | |||||
| HLA matched, related | 119 (39.5) | 22 (31.9) | 63 (38.4) | 34 (50.0) | 0.087 |
| HLA partially matched, related | 99 (32.9) | 32 (46.4) | 56 (34.1) | 11 (16.2) | 0.001 |
| HLA matched, unrelated | 30 (10.0) | 4 (5.8) | 19 (11.6) | 7 (10.3) | 0.402 |
| Stem cell source | <0.001 | ||||
| Peripheral blood | 198 (65.8) | 37 (53.6) | 101 (61.6) | 60 (88.2) | |
| Bone marrow+peripheral blood | 103 (34.2) | 32 (46.4) | 63 (38.4) | 8 (11.8) | |
| Conditioning regimens | |||||
| CY based | 267 (88.7) | 64 (92.8) | 152 (92.7) | 51 (75.0) | <0.001 |
| Anthracycline based | 51 (16.9) | 14 (20.3) | 28 (17.1) | 9 (13.2) | 0.545 |
| TBI based | 138 (45.8) | 25 (36.2) | 85 (51.8) | 28 (41.2) | 0.063 |
| TBI+CY+VP-16/FA | 113 (37.5) | 23 (33.3) | 69 (42.1) | 21 (30.9) | 0.198 |
| Prophylaxis regimens for GVHD | |||||
| CsA+MTX±MMF | 110 (36.8) | 19 (27.9) | 63 (38.4) | 28 (41.8) | 0.202 |
| CsA+MTX+ATG±MMF | 141 (47.2) | 40 (58.8) | 79 (48.2) | 22 (32.8) | 0.010 |
Values are mean ± SD, n (%). ENPH: elevated NT-proBNP and presence of clinical symptoms or signs of heart failure; ENAH: elevated NT-proBNP but absence of symptoms or signs of heart failure; NN: normal NT-proBNP; HSCT: hematopoietic stem cell transplantation; HLA: human leukocyte antigen; CY: cyclophosphamide; TBI: total body irradiation; BU: busulfan; VP-16: etoposide; FA: fludarabine and cytarabine; GVHD: graft-versus-host disease; CsA: ciclosporin A; MTX: methotrexate; MFF: mycophenolate mofetil; ATG: antithymocyte globulin. aLymphoma (n = 16), myelodysplastic syndrome (n = 13), acute mixed lineage leukemia (n = 8), chronic myeloid leukemia (n = 7), biphenotypic acute leukemia (n = 7), etc.